Company Description

Enjamb puts agents across the entire drug program, from preclinical research through clinical trials and approval. Our agents synthesize up-to-date clinical evidence from the literature and real-world data to pinpoint the right endpoints and patient populations; draft and audit regulatory documents like INDs, protocols, SAPs, and NDAs; and run the statistical programming behind them, including SDTM, ADaM, TFLs, and QC, all in one auditable workspace that cuts months off the path from preclinical to clinic and clinic to market.